Theranostics The study in article number 2102816 by Hui Mao and co-workers reports systemic targeted delivery of sub-5 nm theranostic iron oxide nanoparticles carrying the anti-cancer topoisomerase I inhibitor, SN38, to intracranial tumors glioblastoma via enhanced permeability retention effect tumor integrin targeting, leading improved efficacy growth inhibition.
